Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. - Wikidata - wikimedia - TriplyDB

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.

http://www.wikidata.org/entity/Q34396862

about

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration Genetic risk, ethnic variations and pharmacogenetic biomarkers in age-related macular degeneration and polypoidal choroidal vasculopathy Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis.Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics.Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management.Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration.Influence of seasonal sunlight intensity and iris color on the anti-VEGF therapy for neovascular age-related macular degeneration The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Mechanism of inflammation in age-related macular degeneration Complement pathway biomarkers and age-related macular degeneration.Pharmacogenetics and age-related macular degeneration.Risk factors and biomarkers of age-related macular degeneration.A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

P2860

Q27015781-CDA6FAC9-F9D6-4A8C-8A80-615B89A8010A Q28728817-BF991A6C-6031-4116-BCD6-61C332A41239 Q33645265-DAF48421-6D70-4981-A299-7187B062CE29 Q34384420-EB4BE713-F323-4DA7-8352-E2D700E2C073 Q34556444-62195AE1-B7D6-48EC-A395-D062DFD29CD8 Q34781693-AB9D9DF4-67F8-4443-A3CD-F2080AB78FB9 Q36084168-2B101775-BF3D-4D76-9489-7FC1FF64CF56 Q36342997-702B086D-D9C5-4CC0-8B65-1C5A33163AE2 Q36445951-A26E9F4D-12C9-43AD-9A5D-50A7717F7679 Q37053909-4745E8C0-4C47-4367-B42F-5547F4B99BBA Q37166529-7C35A6DD-0DFD-45A8-BD0E-C2DA10B41A66 Q37232214-21666E42-AB2D-4C92-AE61-3E85E68FAD7A Q37250974-36B2344C-ED65-4479-ACF8-35B6DC451594 Q37407241-86DD9562-5010-459C-B205-F1469820ACF9 Q37627442-F25FBED6-7B63-4D32-A1FC-9C806B056741 Q38064846-DEFCBEA5-660C-44D9-96D9-853EB47C642B Q38614012-6F4364AA-9DB3-4498-9D3D-770257AEEFA4 Q38791691-A5AD0227-C82B-4681-8711-72BDB067F9CD Q38828895-230549CE-4512-40FC-A77B-0328134267C9 Q41504310-F4663FDF-C767-4355-A9A7-1D069F722692 Q52559837-D7BC7429-7381-43FB-B519-F37E62ABE10D

P2860

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.

http://www.wikidata.org/entity/Q34396862

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Involvement of genetic factors ...... -related macular degeneration.

@ast

Involvement of genetic factors ...... -related macular degeneration.

@en

Involvement of genetic factors ...... -related macular degeneration.

@nl

type

label

Involvement of genetic factors ...... -related macular degeneration.

@ast

Involvement of genetic factors ...... -related macular degeneration.

@en

Involvement of genetic factors ...... -related macular degeneration.

@nl

prefLabel

Involvement of genetic factors ...... -related macular degeneration.

@ast

Involvement of genetic factors ...... -related macular degeneration.

@en

Involvement of genetic factors ...... -related macular degeneration.

@nl

P1433

Q34396862-2C00443A-782A-4DE9-85E0-785BE8AA10A3

P1476

Q34396862-455E9629-C7C0-46EC-8A77-803F7E539EA9

P2093

Q34396862-17AD340C-DE8E-4998-A313-FCF4BA69554F

Q34396862-6BFCBB2C-9E7F-4EA1-867E-BD6BC3582B6E

Q34396862-A900F67D-CA28-430D-9027-A0D35197EDC2

Q34396862-B0D35068-1230-4503-8732-F68524892429

Q34396862-DD251A11-DBE2-4EDE-9D60-FC79C4342305

P2860

Q34396862-0127EB92-271A-4BF6-9091-A9A764CE75EF

Q34396862-1D48C6AB-E8F6-4ABE-9CDC-50B712C70A21

Q34396862-2443B352-4DF2-4C5E-827A-D8644348C7F8

Q34396862-35FB17BD-FC34-4316-A342-F65620F24151

Q34396862-665F76A0-E579-49F9-83E2-565C749B68C8

Q34396862-67375705-D83F-49A3-8785-54480C94A690

Q34396862-8D4250B4-743D-42FD-86CC-3D6C8DF3ECCC

Q34396862-94512BAB-66F2-4AD5-9C1C-3733501C8BAD

Q34396862-9A773CF3-DB83-4A17-952C-21AD9ACD7070

Q34396862-9CF3F8A9-D5D7-442C-8DBF-A38F715D6DDE

P304

Q34396862-0F03FC93-A0A9-4001-8642-1C2EB6431016

P31

Q34396862-F5766053-236F-49D8-9603-6A2C4B343C0F

P478

Q34396862-C495AC3A-1F1E-4649-90C8-4886AF476D91

P577

Q34396862-708E2F92-9DDE-4157-B98C-0C0BC7F45FBF

P698

Q34396862-E66E38C3-1C89-4BBB-923C-AAFCB6073F41

P932

Q34396862-A31DFEBC-190A-49F6-A44E-C65F5DC3B875

P1433

Molecular Vision

P1476

Involvement of genetic factors ...... -related macular degeneration.

@en

P2093

Andrzej Palucha

http://www.w3.org/2001/XMLSchema#string

Anna Nowinska

http://www.w3.org/2001/XMLSchema#string

Edward Wylegala

http://www.w3.org/2001/XMLSchema#string

Jaroslaw Pilat

http://www.w3.org/2001/XMLSchema#string

Slawomir J Teper

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab for neovascular age-related macular degeneration

Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study.

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential.

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.

Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population.

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel.

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.

P304

2598-2604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21151600

http://www.w3.org/2001/XMLSchema#string

P932

3000236

http://www.w3.org/2001/XMLSchema#string